Trans-1-[2-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-5-methyl-1,3-dioxan-5-yl]-1-(4-morpholinyl)methanone methanesulfonate, with CAS number 218162-38-0, is a complex organic compound characterized by its multi-functional structure. It features an imidazole ring, which is known for its biological activity, particularly in pharmaceuticals. The presence of a fluorophenyl group enhances its lipophilicity, potentially improving its ability to cross biological membranes. The methanesulfonate moiety indicates that it is a salt, which can influence its solubility and stability in various solvents. This compound may exhibit significant pharmacological properties, making it of interest in medicinal chemistry, particularly in the development of therapeutic agents. Its structural complexity suggests potential interactions with biological targets, and its synthesis would require careful consideration of stereochemistry and functional group compatibility. Overall, this substance represents a class of compounds that could be explored for their utility in drug development and other applications in chemistry and biochemistry.

trans-1-[2-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-5-methyl-1,3-dioxan-5-yl]-1-(4-morpholinyl)methanone methanesulfonate

218162-38-0: Trans-1-[2-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-5-methyl-1,3-dioxan-5-yl]-1-(4-morpholinyl)methanone methanesulfonate, with CAS number 218162-38-0, is a complex organic compound characterized by its multi-functional structure. It features an imidazole ring, which is known for its biological activity, particularly in pharmaceuticals. The presence of a fluorophenyl group enhances its lipophilicity, potentially improving its ability to cross biological membranes. The methanesulfonate moiety indicates that it is a salt, which can influence its solubility and stability in various solvents. This compound may exhibit significant pharmacological properties, making it of interest in medicinal chemistry, particularly in the development of therapeutic agents. Its structural complexity suggests potential interactions with biological targets, and its synthesis would require careful consideration of stereochemistry and functional group compatibility. Overall, this substance represents a class of compounds that could be explored for their utility in drug development and other applications in chemistry and biochemistry.

RPR-200765A selectively inhibits p38 MAP kinase, blocks TNFalpha in vitro (EC50 = 110 nM) and in mice (ED50 = 6 mg/kg), and shows promise in RA treatment.

CAS 218162-38-0

trans-1-[2-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]-5-methyl-1,3-dioxan-5-yl]-1-(4-morpholinyl)methanone methanesulfonate

RPR-200765A Mesylayte

Ref: TM-T69831